Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Evaluation of Circulating Tumor DNA Guided Surveillance Strategy of Stage III Colorectal Cancer: an Open, Prospective, Randomized Controlled Cohort Study
Not Applicable
Recruiting
- Conditions
- Circulating Tumor DNAStage III Colorectal Cancer
- Interventions
- Diagnostic Test: ctDNA dynamic monitoring
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 316
- Registration Number
- NCT05161585
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
Phase 2
Recruiting
- Conditions
- Stomach NeoplasmsEsophagogastric Junction DisorderNeoadjuvant TherapyChemoradiotherapyImmunotherapyGastrectomyAdenocarcinomaAdjuvant Therapy
- Interventions
- Drug: Tegafur-Gimeracil-OteracilRadiation: Concurrent chemoradiationProcedure: D2/R0 gastrectomy
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 152
- Registration Number
- NCT05161572
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Clinical Phenotype and Omics Study of KCNQ2-related Epilepsy
Recruiting
- Conditions
- KCNQ2-related Epilepsy
- Interventions
- Other: Electrophysiological detection of KCNQ2 mutationOther: Multi-modal brain image and EEGOther: Omics testing
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT05157737
- Locations
- 🇨🇳
Children's Hospital of Fudan University, Shanghai, Shanghai, China
Titration of Intraoperative PEEP in Patients Undergoing Robotic Assisted Laparoscopic Prostatectomy
Not Applicable
Completed
- Conditions
- Positive End Expiratory Pressure
- Interventions
- Other: Titration of Optimal Positive End-expiratory Pressure
- First Posted Date
- 2021-12-13
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 95
- Registration Number
- NCT05155371
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
Active, not recruiting
- Conditions
- Metastatic Esophageal Squamous Cell Carcinoma
- Interventions
- Drug: Anti-PD-1 Immune Checkpoint Inhibitors
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT05142709
- Locations
- 🇨🇳
Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The 1st affiliated hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Fruquintinib in the Treatment of Soft Tissue Sarcoma
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 31
- Registration Number
- NCT05142631
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Axillary Sentinel or Targeted Lymph Node Biopsy Alone After Neoadjuvant Chemotherapy in Node-positive Breast Cancer
Phase 2
- Conditions
- Breast Cancer Female
- Interventions
- Procedure: sentinel lymph node biopsy or targeted axillary dissection alone
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT05141630
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2021-11-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 10
- Registration Number
- NCT05138159
- Locations
- 🇨🇳
Fudan University, Shanghai, China
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
Phase 1
- Conditions
- GlioblastomaColon CancerMedulloblastomaHepatocellular Carcinoma
- Interventions
- Biological: NKG2D-based CAR T-cells
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2021-11-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 3
- Registration Number
- NCT05131763
- Locations
- 🇨🇳
Xunyang Changchun Shihua Hospital, Jiujiang, Jiangxi, China
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT05124431
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath